Symic Appoints Manish Anand as Vice President of Regulatory Affairs and Quality

SAN FRANCISCO, June 20, 2016 /PRNewswire/ -- Symic, a clinical stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix, today announced the appointment of Manish Anand as Vice President of Regulatory Affairs and Quality. Mr. Anand will lead the company's regulatory strategy, global filings and quality efforts.

"Mr. Anand's wide range of experience in the area of regulatory affairs provides an excellent fit for Symic as we advance our existing clinical programs and broaden our pipeline," said Ken Horne, Chief Executive Officer. "Given the potential of our platform to address a wide range of indications, his experience will apply both in the near future and in ways that we are just beginning to explore at this stage of the company's growth."

Mr. Anand brings to the company 14 years of industry experience in advancing drug candidates from preclinical stages of development to marketing as well as experience in post-marketing development. He has had responsibility for interactions with international regulatory agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Mr. Anand has been involved in the development of drugs, biologics, blood products and vaccine therapies for a diverse range of therapeutic areas such as hematology, oncology, CNS, inflammation and orphan disease. Prior to joining Symic, Mr. Anand was Director of Regulatory Affairs at Portola Pharmaceuticals. Mr. Anand has also served in regulatory affairs positions at BioMarin, Vanda, MacuSight and Medimmune. Mr. Anand received a M.S. in Biotechnology from the Johns Hopkins University and a B.S. in Chemistry from Lafayette College.

About Symic Biomedical

Symic is a clinical stage biotherapeutics company developing novel compounds that target and affect the extracellular matrix (ECM), the non-cellular component of tissue. The ECM plays a critical role in a wide variety of processes involved in acute and chronic indications. Symic's proprietary compounds function like proteoglycans, which are naturally occurring macromolecules that play important structural and regulatory functions in the ECM. Symic currently has two clinical candidates, one in vascular injury and the other in osteoarthritis. In addition, Symic has several preclinical programs in oncology, fibrosis and CNS disorders.

For additional information please visit the company's website at http://www.symic.bio, LinkedIn page www.linkedin.com/company/symic-bio/ or follow on Twitter at www.twitter.com/symicbio.

Media Contacts
David Schull or Rich Allan
Russo Partners, LLC
(212) 845-4271
(646) 942-5588
[email protected]
[email protected]

SOURCE Symic

Related Links

http://www.symic.bio